M402 monotherapy or in combination with docetaxel shows survival benefits in the orthotopic murine mammary carcinoma 4T1 model.

<p>(A) Groups of female BALB/c mice (n = 20) were inoculated orthotopically with 1×10⁵ 4T1 cells in the 4th mammary fat pad on day 0. M402 treatment delivered by sc implanted osmotic pumps at 40 mg/kg/day started on day 1. Primary tumors were removed on day 10. Survival of the M402 treated group was significantly longer than that of the saline control group (P<0.02 by Log-Rank test). (B–D) Groups of female BALB/c mice (n = 16) were inoculated orthotopically with 5×10⁴ 4T1-luc2-1A4 cells in the 4th mammary fat pad on day 0. M402 treatment delivered by sc implanted osmotic pumps at 40 mg/kg/day started on day 1. Primary tumors were removed on day 10 by surgery. Weekly ip injection of saline or docetaxel (10 mg/kg) started on day 14. After primary tumor resection, animals were monitored twice weekly with bioluminescent imaging. (B) Whole body bioluminescence (Mean±SEM) quantified as photons/second over time. (C) Bioluminescence imaging of all the experimental animals on day 29. (D) Kaplan-Meier survival curve. Survival of the M402 and docetaxel combination group was significantly longer than that of the saline control and the docetaxel monotherapy group (P<0.0001 and P<0.05, respectively, by Log-Rank test).